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Available online 14 November 2017Background: Sensitization in early childhood may precede respiratory allergy in adolescence.
Methods: IgE reactivity against 132 allergen molecules was evaluated using the MeDALL microarray in sera ob-
tained from a random sample of 786 children at the age of 4, 8 and 16 years in a population based birth cohort
(BAMSE). Symptoms were analyzed by questionnaire at ages 4, 8 and 16 years. Clinically and independent rele-
vant allergen molecules accounting for ≥90% of IgE reactivities in sensitized individuals and at all time-points
were identiﬁed as riskmolecules and used to predict respiratory allergy. The datawas replicated in theManches-
ter Asthma and Allergy Study (MAAS) birth cohort by studying IgE reactivity with the use of a commercial IgE
microarray. Sera were obtained from children at the ages of 3, 5, 8 and 11 years (N = 248) and the outcome
was studied at 11 years.
Findings: In the BAMSE cohort 4 risk molecules could be identiﬁed, i.e.: Ara h 1 (peanut), Bet v 1 (birch), Fel d 1
(cat), Phl p 1 (grass). ForMAAS the corresponding number of molecules was 5: Der p 1 (dust mite), Der f 2 (dust
mite), Phl p 1 (grass), Phl p 5 (grass), Fel d 1 (cat). In BAMSE, early IgE reactivity to ≥3 of 4 allergenmolecules at
four years predicted incident and persistent asthma and/or rhinitis at 16 years (87% and 95%, respectively). The
corresponding proportions in theMAAS cohort at 16 years were 100% and 100%, respectively, for IgE reactivity to
≥3 of 5 risk molecules.
Interpretations: IgE reactivity to a few allergenmolecules early in life identiﬁes childrenwith a high risk of asthma
and/or rhinitis at 16 years. These ﬁndings will be of importance for developing preventive strategies for asthma
and rhinitis in children.
Crown Copyright © 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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IgE sensitization in early childhood is associatedwith increased risks
of asthma, rhinitis and eczema but there are no reliable parameters that
can predict the transition from IgE sensitization to the development of
respiratory allergy later in life (Illi et al., 2001; Illi et al., 2004;
Brockow et al., 2009). This accounts for both aero- and food allergens.
Allergic diseases are heterogeneous in terms of phenotypes and trajec-
tories (Belgrave et al., 2014; Ranciere et al., 2013). In most studies, IgE
antibody reactivity has been analyzed using singleplex assays with a
limited number of allergen extracts (Illi et al., 2001; Illi et al., 2004;
Brockow et al., 2009; Chiu et al., 2014) that cannot distinguish genuine
sensitization from cross-reactivity. However, with multiplex platforms
using allergen molecules spotted on a microarray, IgE to N100 deﬁned
allergen components can be simultaneously analyzed (Hiller et al.,
2002; Canonica et al., 2013; Melioli et al., 2013; Patelis et al., 2012;
Hatzler et al., 2012; vanHage et al., 2017). This allows anunprecedented
precision of mapping the sensitization proﬁles down to the level of dis-
ease-causing allergen molecules (Bousquet et al., 2016).
Birth cohorts are essential for understanding the life course of allergy
(Bousquet et al., 2014), allowing to identify windows of opportunity for
preventive strategies (Westman et al., 2017). The role of sensitization to
speciﬁc allergen molecules or to patterns of molecules in childhood for
predicting development of allergic diseases in adolescence is unknown.
We hypothesized that early age IgE sensitization to speciﬁc allergen
molecules would be a strong predictor of risk to develop respiratory al-
lergy from childhood to adolescence. Since there are obvious differences
in regional sensitizations we aimed to investigate two cohorts from dif-
ferent regions to understand heterogeneity and improve generalizabili-
ty of the results.
Our goalwas to investigate if IgE recognition of certain allergenmol-
ecules early in life could be linked to respiratory allergy, rhinitis and/or
asthma, in childhood up to adolescence. For this purpose sera from chil-
dren from the Swedish birth cohort BAMSE (Barn/Children, Allergy, Mi-
lieu, Stockholm, Epidemiological study) were analyzed using a large
panel ofmicro-arrayed allergenmolecules and the resultswere replicat-
ed in the Manchester Asthma and Allergy Study (MAAS) birth cohort
(Custovic et al., 2002).
2. Methods
2.1. Study Design and Participants
Discovery population: BAMSE is an unselected population-based
birth cohort comprising 4089 children from representative areas of
Stockholm (Wickman et al., 2002). Parents of all children born between
1994 and 1996 in certain areas of Stockholmwere invited to participate.
The BAMSE cohort comprised 4089 infants, corresponding to 75% of the
eligible subjects. The children were recruited postnatally and follow-
ups were performed repeatedly including collection of questionnaire
data on exposure and outcome, mainly of asthma, rhinitis and eczema.
A period prevalence of reported symptoms during the last 12months
was assessed. When the infants were about twomonths old, the par-
ents were asked to ﬁll in a detailed questionnaire regarding parental
allergy, background factors and other relevant exposures. Follow-
ups were performed at 1, 2, 4, 8, 12 and 16 years with a response
rate of 78% at the latest follow-up. Allergy testing based on venous
blood samples was performed in 2605; 2470 and 2547 children at
four, eight and 16 years, respectively, which corresponds to 64%,
60% and 62%, of children at baseline. In 1699 children (42%) sera
were available from all three time points, and 800 children were ran-
domly picked for IgE analyses (Fig. 1A) (Asarnoj et al., 2016;
Westman et al., 2015).
Replication population: MAAS is a population based-cohort of
1184 prenatally enrolled children. 248 participants attended all ﬁve
follow-ups. For each follow-up the attendance rate was: at ages3 years, (N = 248), 5 years, (N = 588), 8 years (N = 543), 11 years
(N = 461) and 16 years (N = 772). Children from whom sera were
available at all ﬁrst three time points were included (Supplementary
Fig. 1B) (Custovic et al., 2002; Prosperi et al., 2014).
Ethics committees have approved both studies and parents have
provided written informed consent.2.2. Deﬁnitions and Data Sources
Validated questionnaires were used in both studies to ascertain
symptoms, physician-diagnosed illnesses and medication use.2.2.1. Deﬁnitions of exposures and outcomes
2.2.1.1. Parental Allergy.Mother and/or father with doctor's diagnosis of
asthma and asthmamedication and/or doctor's diagnosis of hay fever in
combination with furred pets- and/or pollen allergy at the time of the
baseline questionnaire.2.2.1.2. Breast Feeding. Four months or more of exclusive breastfeeding.2.2.1.3. Second hand tobacco smoke. Either of the parents smoked at least
one cigarette per day at the time of the ﬁrst questionnaire.2.2.1.4. Socio-economic Status. Assessed using the Nordic standard occu-
pational classiﬁcation and Swedish socio-economic classiﬁcation (Occu-
pations in Population and Housing Census 1985 (FoB 85) according to
Nordic standard occupational classiﬁcation (Nordisk yrkesklassiﬁcering,
NYK) and Swedish socio-economic classiﬁcation (Socioekonomisk
indelning, SEI)1989. Available at: http://www.scb.se/statistik/_
publikationer/OV9999_1982A01_ BR_X11%C3%96P8204.pdf. Accessed
April 27, 2014.2.2.1.5. Asthma. Children fulﬁlled the criteria of asthma at ages one and
two years if they had at least three episodes of wheeze in combination
with inhaled corticosteroids and/or signs of bronchial hyperreactivity
without concurrent upper respiratory infection during the previous
12 months (Wickman et al., 2003). Asthma at age 4, 8, 12 and
16 years was deﬁned as having at least four episodes of wheeze in the
previous 12 months or at least one episode of wheeze in combination
with occasional or regular use of prescribed inhaled corticosteroids in
the last 12 months (Ballardini et al., 2012).2.2.1.6. Rhinoconjunctivitis. Deﬁned at all ages as “sneezing, runny or
blocked nose in the last 12monthswithout common cold or ﬂu, accom-
panied by itchy, watery eyes” according to the deﬁnition of the Interna-
tional study of asthma and allergies in childhood (ISAAC) (validated in
Swedish language) (Asher et al., 2006).2.2.1.7. Eczema. Deﬁned at all ages as having dry skin in combination
with a pruritic rash for two or more weeks with typical localization
(face or arm/leg ﬂexures or wrists, ankles or neck) in the past
12 months and/or a doctor's diagnosis of eczema (Bohme et al.,
2002).
The deﬁnitions were identical for asthma and rhinitis and consid-
ered similar for eczema in the two populations. Allergic multimorbidity
was deﬁned as simultaneously having asthma and rhinitis. Incident dis-
ease was deﬁned as disease reported at eight or 16 years without prior
disease. Persistent disease was deﬁned as disease at both 4 and 16 years
for BAMSE and at 3 and 16 years for MAAS irrespective of disease at a
younger age.
Fig. 1. A. (BAMSE) Flow chart of children in the study base and study population as well as for those remaining for statistical analysis of onset and persistency of asthma, rhinitis and/or
eczema at 16 years. Analyses in relation to sensitization to allergenmolecules at 4 yearswith (persistency) andwithout (onset) childrenwith any of asthma (A), rhinitis (R) or eczema (E)
at 4 years. B. (MAAS). Flow chart of children in the study base and study population as well as for those remaining for statistical analysis of onset and persistency of asthma, rhinitis and/or
eczema at 16 years. Analyses in relation to sensitization to allergenmolecules at 3 yearswith (persistency) andwithout (onset) childrenwith any of asthma (A), rhinitis (R) or eczema (E)
at 3 years.
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2.3.1. Multiplex Microarray
For analysis of BAMSE samples, a customized allergen chip based on
ISAC technology (Thermo Fisher Scientiﬁc, Uppsala, Sweden) that was
developed in the FP7-funded EuropeanUnionprojectMeDALL (MeDALL
Chip) was used at the Medical University of Vienna (EK1641/
2014)(Lupinek et al., 2014) and for MAAS, the ImmunoCAP ISAC (Ther-
mo Fisher) was employed (Gadisseur et al., 2011). The same detectionsystems and cut-off levels of 0.3 ISU (ISAC standardized units) were
used in both assays. In the ﬁnal dataset, 132 allergen molecules from
51 allergen sources were studied in BAMSE and 99 allergen molecules
from 44 allergen sources in MAAS.
2.3.2. MeDALL Allergen Chip
Allergy testingwas based onvenous blood samples drawn at 4, 8 and
16 years. All sera were analyzed anonymously. The MeDALL allergen-
chip represents a comprehensive collection of spotted allergen
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(Lupinek et al., 2014). Aliquots of 30 μl serumwere incubated on themi-
croarray and after 120 min of incubation at room temperature, slides
were washed, and ﬂuorochrome-labeled IgE speciﬁc detection antibody
(Thermo Fisher) was added and incubated for 30 min at room temper-
ature. Chips were then washed, dried and analyzed using a Laser Scan
Confocal microarray reader (LuxScan 10 K/A; Capital-Bio, Beijing,
China). The resultswere evaluated using PhadiaMicroarray Image Anal-
ysis (MIA) software and reported in ISAC Standardized Units for IgE de-
tection (ISU) by using a standard calibration curve. Calibration for IgE
has been established for theMeDALL allergen-chip by relating antibody
levels to several allergens detected by microarray with the respective
results from ImmunoCAP measurements (Lupinek et al., 2014). The
cut off was 0.3 ISU-E according to instructions from the manufacturer.
In this studywe used 132 allergenmolecules for analysis corresponding
to 41 allergen sources which have recently been described and validat-
ed (Lupinek et al., 2014). Allergen molecules from venoms (bee and
wasp), anisakis, experimental molecules and glycosylated molecules
were excluded (Cabauatan et al., 2014), as were allergen molecules
not relevant for the regions. From those allergens where preparations
from several different expression systemswere spotted, only that prep-
aration which gave results with highest reproducibility was used for
analysis.2.4. Statistical Analysis
Prevalence rates were expressed in percent of the total number of
observations available and with 95% conﬁdence intervals. The median
IgE concentration and interquartile range (IQR) for each speciﬁc aller-
gen componentwere calculated. Quintile regressionwas used for detec-
tion of changes of IgE over time and for tests of equality of proportions
z-tests were used.
We identiﬁed clinically relevant allergen molecules responsible for
sensitization in at least 90% of all sensitized individuals at each of the
three ages. For this procedure IgE-levels ≥1 ISU were required in order
to reduce misclassiﬁcation of sensitization. With this approach the
number of sensitizingmolecules responsible for the cumulative propor-
tion of sensitized individuals increased rather linearly from 55% to just
below 90%, and to turn exponential with little additive effect on the
overall sensitization rate thereafter (Fig. 1 in the supplementry appen-
dix). In order to identify clinically relevant molecules, hereafter called
key allergen molecules, a combined rank of the prevalence and median
IgE-level (ISU) for each allergenmolecule was constructed separately at
the three ages. From the initial 132 molecules 16, 13 and 9 molecules
were identiﬁed as potential risk molecules at 4, 8 and 16 years, respec-
tively (Table 1A-C in the supplementray appendix). Over the entire time
period of 12 years, 18 sensitizing key molecules could be identiﬁed in
total. Because allergic children are more likely to be sensitized to multi-
ple allergens (Wickman et al., 2014), some of which may be clinically
relevant and some only cross-reacting, we wanted to identify risk aller-
gen molecules of clinical relevancy. For this identiﬁcation we required
that the risk allergen molecule should be identiﬁed at all three time
points (4, 8, 16 years) and should contribute to at least 1% to the cumu-
lative proportion of sensitization.
Odds ratios (ORs) were estimated using multiple logistic regression
models and 95% conﬁdence intervals (95% CI). Fitted predicted proba-
bility curves according to the levels of speciﬁc IgE to different allergen
components were plotted using the results from the logistic regression.
Previously identiﬁed confounders for sensitization and disease develop-
ment changed the odds ratios by b10%. Therefore, all analyseswere per-
formed unadjusted. Positive and negative predictive values (PPV and
NPV) respectively, as well as binomial exact 95% conﬁdence intervals
(95% CI) were calculated. A P-value b 0.05 was considered signiﬁcant.
All statistical analyses were performed with the software program
STATA 13 (College Station, TX, USA).3. Results
3.1. Demographic Data
Flow charts of the selection of children from each cohort as well
as outcomes of asthma/rhinitis/eczema at 16 years are presented in
Fig. 1A–B and Table 1).
3.2. Evolution of IgE Reactivity to Allergen Molecules
In BAMSE, 199 (25.3%), 319 (40.6%) and 409 (52.0%) children at 4, 8
and 16 years of age showed IgE reactivity to at least one of the 132mol-
ecules (Fig. 2A). The corresponding numbers in MAAS were 46 (18.6%),
172 (29.4%), 184 (33.9%) and 194 (42.1%) children at 3, 5, 8 and 11 years
for at least one of the 99molecules (Fig. 2B). For childrenwith resolving
sensitization, i.e. positive at one time point, but negative (b0.3 ISU) at
the next follow-up for the same allergen molecule, IgE-levels at the
ﬁrst time point was below 1 ISU in 87.7% and 92.9% at 8 and 16 years,
respectively.
3.3. Identiﬁcation of IgE to Key and Risk Allergen Molecules
Eighteen different key molecules were identiﬁed in BAMSE (Tables
1A–C in the supplementary appendix) and 21 in MAAS (Tables 1 D–G
in the supplementary appendix) at the statistical analyses. These mole-
cules belonged to both inhalant and food allergen sources.
In BAMSE, 4 risk molecules were identiﬁed among the 18 key mole-
cules: Ara h 1 (peanut); Bet v 1 (birch pollen); Fel d 1 (cat) and Phl p 1
(timothy grass pollen). At 4, 8 and 16 years 83%, 84% and 82% of all
sensitized children could be identiﬁed by the 4 BAMSE risk molecules
(Fig. 2A).
In MAAS, 5 risk molecules among the 21 key molecules were identi-
ﬁed: Der p 1 and Der f 2 (house dust mites; Dermatophagoides
pteronyssinus/farinae); Phl p 1 and Phl p 5 (timothy grass pollen), and
Fel d 1 (cat). At 3, 5, 8 and 11 years 95%, 90%, 86% and 94% of all
sensitized children could be identiﬁed by the 5 MAAS risk molecules
(Fig. 2B).
3.4. IgE to Risk Molecules in Asthma and/or Rhinitis Trajectories
In BAMSE, sensitization to any of the 4 BAMSE risk molecules at
4 years was the strongest predictor of the risk of developing rhinitis,
asthma and to some extent eczema until the age of 16 years. Children
sensitized to 1, 2, 3 or 4 risk molecules showed a probability of 30%,
50%, 70% and 85% of rhinoconjuctivitis at 16 years, respectively. For
key and full panel allergen molecules, children needed to be sensitized
to 10 and 19 molecules, respectively, for having an 85% probability of
having rhinoconjunctivis at 16 years (Fig. 3A). Results were similar for
asthma and, to less extent, for eczema.
In MAAS, children sensitized to any of the 5 MAAS risk molecules at
3 years had a signiﬁcantly higher risk of developing rhinitis, asthma and,
to someextent, eczema at 16 years than those sensitized to any of the 21
keymolecules or to any of the total 99molecules (Fig. 3B). If IgE reactiv-
ity was present to 3 of 5 risk molecules at 3 years, the probability at
16 years was 87% for rhinitis and 76% for asthma.
As sensitization at 4 years in BAMSE and at 3 years in MAAS did not
affect eczema alone at 16 years (OR= 1.0), further investigation on the
impact of early sensitization on allergic multimorbidity was performed
for rhinitis and asthma only.
3.5. IgE to Risk Molecules for Allergic Multimorbid Disease
For both rhinitis and asthma, i.e. multimorbid disease, the risk of in-
cident (BAMSE Fig. 4, MAAS Fig. 4B) or persistent (BAMSE Fig. 4C,MAAS
Fig. 4D) disease was most signiﬁcant using the 4-risk molecule ap-
proach in BAMSE and the 5-risk molecule approach in MAAS. In
Table 1
Background characteristics at baseline and at 4, 8 and 16 years (BAMSE cohort) and at 3, 5, 8, 11 and 16 years (MAAS cohort) of children in the study base and children in the study
population.
The BAMSE cohort (study
base) (N = 4089)
BAMSE study population
(N = 786)
The MAAS cohort (study
base) (N = 1184)
MAAS study population
(N = 848)
n % 95% CI n % 95% CI N % 95% CI n % 95% CI
At baseline
Female 2024 49.5 48.0–51.0 395 50.3 46.7–53.8 542 45.8 42.9–48.6 389 45.9 42.5–49.2
Parental allergy 1200 29.7 28.3–31.1 260 33.3 30.0–36.7 444 39.1 36.3–42.0 340 41.5 38.1–44.9
Breastfed ≥4 months 3116 79.5 78.2–80.8 616 79.4 76.4–82.2 435 39.0 36.1–41.9 339 41.5 38.2–44.9
Parents smoking 855 21.0 19.8–22.3 161 20.6 17.8–23.6 328 32.0 29.1–34.9 250 31.3 28.1–34.5
Young mother at birth (≤25 years) 319 7.8 7.0–8.7 58 7.4 5.7–9.4 154 13.8 11.8–15.9 101 12.6 10.3–14.9
White collar parent 695 17.3 16.1–18.5 114 14.6 12.2–17.3 464 61.5 58.1–65.0 357 61.4 57.5–65.4
Pet (cat and/or dog) at home 590 14.4 13.4–15.5 115 14.6 12.2–17.3 389 33.5 30.8–36.3 284 34.1 30.9–37.3
Older siblings 1980 48.4 46.9–50.0 393 50.0 46.4–53.6 599 55.7 52.7–58.6 464 56.0 52.6–59.4
At 4 years At 3 years
Asthma 537 14.5 13.4–15.7 135 17.4 14.8–20.2 155 14.4 12.3–16.6 25 10.1 6.3–13.9
Rhinitis 386 10.5 9.5–11.5 89 11.4 9.3–13.9 43 3.9 1.9–5.8 13 5.2 2.4–8.0
Asthma and/or Rhinitis (AR) 787 21.5 20.2–22.9 188 24.3 21.3–27.5 184 17.1 14.9–19.4 33 13.3 9.0–17.6
At 5 years
Asthma 135 17.4 14.8–20.2 123 21.3 17.9–24.6
Rhinitis 89 11.4 9.3–13.9 156 27.2 22.6–31.9
Asthma and/or Rhinitis (AR) 188 24.3 21.3–27.5 231 40.2 36.2–44.2
At 8 years At 8 years
Asthma 337 10.0 9.0–11.0 94 12.0 9.8–14.5 182 17.8 15.4–20.1 87 16.2 13.0–19.3
Rhinitis 453 13.3 12.2–14.5 129 16.5 13.9–19.3 297 28.9 26.1–31.7 139 25.9 22.2–29.6
Asthma and/or Rhinitis (AR) 642 19.0 17.7–20.4 176 22.6 19.7–25.7 385 37.6 34.6–40.5 187 34.8 30.8–38.9
At 11 years
Asthma 190 20.8 18.2–23.4 99 21.7 16.9–24.4
Rhinitis 314 33.8 30.2–37.3 151 32.8 28.5–37.1
Asthma and/or Rhinitis (AR) 390 42.4 39.2–45.6 187 41.0 36.5–45.5
At 16 years At 16 years
Asthma 342 10.8 9.8–12.0 93 12.0 9.8–14.5 133 17.9 15.1–20.6 68 17.7 13.9–21.5
Rhinitis 789 25.4 23.9–26.9 211 27.6 24.4–30.9 309 41.2 37.7–44.7 154 40.0 35.1–44.9
Asthma and/or Rhinitis (AR) 918 29.6 28.0–31.2 242 31.6 28.3–35.0 350 46.8 43.2–50.4 177 46.0 41.0–51.0
Fig. 2.A. (BAMSE). Prevalence of IgE reactivity (%, y-axis) in the population of 786 children
at ages 4, 8, 16 years (x-axis) using different sets of molecules at all ages (132), as well as
key (18) and risk molecules (4) identiﬁed at 4 years. Prevalence indicates IgE reactivity to
any of themolecules in each of the three groups. Four riskmoleculeswere identiﬁed: Ara h
1 (peanut); Bet v 1 (birch pollen); Fel d 1 (cat) and Phl p 1 (timothy grass pollen). B.
(MAAS). Prevalence of IgE reactivity (%, y-axis) in the population of 848 children at ages
3, 5, 8, 11 years (x-axis) using different sets of molecules at all ages (99), as well as key
(21) and risk molecules (5) identiﬁed at 3 years. Prevalence indicates IgE reactivity to
any of the molecules in each of the three groups. Five risk molecules were identiﬁed:
Der p 1 (Dermatophagoides pteronyssinus); Der f 2 (Dermatophagoides farinae), Phl p 1
and Phl p 5 (timothy grass pollen), and Fel d 1 (cat).
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were found to be sensitized to all 4 risk molecules at 4 years. However,
for IgE reactivity to 2 or 3 risk molecules at 4 years the probability of in-
cident asthma and or rhinitis was 69% and 87%, respectively. For key and
full panel allergen molecules children needed to be sensitized to 7 and
10 molecules, respectively, to have a 87% probability of having
multimorbid respiratory disease at 16 years. For MAAS the correspond-
ing proportions for IgE reactivity at 3–5 years and incident respiratory
disease at 8 or 16 was for 2 or 3 risk molecules 57.4% and 66.7% and
for 4 of the 5 risk molecules 100%.
For persistent multimorbid disease in BAMSE, children sensitized to
1, 2, 3 or 4 riskmolecules showed a probability of 28%, 72%, 95% and 98%.
For key and full panel allergen molecules children needed to be sen-
sitized to 8 and 12 molecules, respectively, to have a 98% probability of
having multimorbid disease at 16 years. The corresponding probabili-
ties for disease at 16 years in relation to IgE reactivity to at least 3 of
the 5 riskmolecules in MAAS at 3 years were 90% and 100% if sensitized
to all 5 (Fig. 4C–D).
The positive predictive value (PPV) for asthma or rhinitis in BAMSE
ranged from 73.1% to 94.7% with increasing number of risk molecules
at 4 years, p b 0.001 (Table 2A). For the 3 year olds in MAAS 100% PPV
was achieved for asthma and/or rhinitis (Table 2B).
4. Discussion
This is the largest study to date where children from a population-
based birth cohort (BAMSE) have been analyzedwith 132 allergenmol-
ecules from early childhood to adolescence, corresponding to N300,000
single IgE tests to individual allergenmolecules. The studywas replicat-
ed in a comparable birth cohort (MAAS) using 99 of the BAMSE allergen
molecules. The results reveal that the detection of IgE against a handful
Fig. 3. A. (BAMSE): Probability of rhinitis, asthma or eczema at 16 years in relation to the number of sensitizing risk (green), key (blue) and full panel (red) allergenmolecules at 4 years.
Probabilities and conﬁdence intervals (hatched lines) were obtained from logistic regressionmodels. Logisticmodels did not include respiratory allergic disease at 4 or 8 years. B. (MAAS):
Probability of rhinitis, asthma or eczema at 11 years in relation to number of sensitizing risk (green), key (blue) and full panel (red) allergen molecules at 3 years. Probabilities and
conﬁdence intervals (hatched lines) were obtained from logistic regression models. Logistic models did not include respiratory allergic disease at 3 or 5 years.
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signature to predict respiratory allergy until adolescence in two geo-
graphically different populations. We were able to predict incident or
persistent asthma and rhinitis with N90% probability in both studies
by IgE reactivity to the risk molecules at age 3–5 years, albeit with
broad conﬁdence intervals. Interestingly, the risk for incident or persis-
tent multimorbid disease was even more signiﬁcant than for singledisease. To our knowledge, our study is the ﬁrst to show this association
in two different cohorts with different exposure backgrounds.
We used an investigator driven strategy, with a priori deﬁned
criteria for key and risk allergen molecules associated with allergic dis-
ease. Using this approach, it was possible to obtain a detailed pattern of
the IgE recognition repertoire and link the molecular responses to clin-
ical symptoms in both cohorts. We identiﬁed key allergen molecules
Fig. 4. A. (BAMSE) Probability of allergicmultimorbidity (asthma and rhinitis) reported at 8 or 16, but not at 4 years of age. B. (MAAS). Probability of allergicmultimorbidity (asthma and
rhinitis) reported at 8 or 16, but not at 3 or 5 years of age. C. (BAMSE). Probability of having allergic multimorbidity (asthma and rhinitis), i.e. disease at both 8 and 16 years irrespective of
disease at 4 years of age. D. (MAAS). Probability of having allergic multimorbidity (asthma and rhinitis), i.e. disease reported at both 8 and 16, irrespective of disease at 3–5 yrs.
97M. Wickman et al. / EBioMedicine 26 (2017) 91–99accounting for 90% of IgE reactivities at each of the studied time points
(18/132 in BAMSE and 21/99 in MAAS) and risk molecules (4 in
BAMSE and 5 inMAAS) associatedwith development of allergic disease.
These risk molecules were the major allergens from birch and timothy
grass pollen, aswell as those fromcat andpeanut in the Swedish setting,
whereas the major allergens of dust mites, grass and cat were recog-
nized in the UK environment.
4.1. Strengths and Limitations
A major strength of both birth cohorts is their design to primarily
study the development of allergic disease in childhood up to adoles-
cence using questionnaire and serological data serially available in a
large number of children at similar ages both for detection of IgE reactiv-
ity and outcome. In addition, nearly the same panel of allergenTable 2A
BAMSE: Persistent asthma and/or rhinitis (with any of asthma or rhinitis at 4 yrs. and any of th
Number of risk molecules at 4 yrs Freq. % TP FP TN FN Sensitiv
0 69.5
1 13.0 19 7 84 55 25.7 (16
2 8.0 14 2 84 55 20.3 (11
3–4 9.5 18 1 84 55 24.7 (15
TP, True Positive; FP, False Positive; TN, True Negative; FN, False Negative; PPV, Positive Predicmolecules was used for both cohorts. Furthermore, using cohorts from
two different geographical locations, with a total number of 1034 chil-
dren generating similar conclusions, suggests the results to be general-
izable across populations. A limitation could be that IgE measurements
on the chip are performed under conditions of low amounts of allergen
immobilized to the solid phase, whichmay be affected by allergen-spe-
ciﬁc IgG antibodies (Lupinek et al., 2016). However, the MeDALL aller-
gen-chip has been carefully evaluated with respect to speciﬁcity and
sensitivity andwas found to bemore sensitive and speciﬁc for detecting
IgE sensitization than allergen-extract-based skin prick testing and con-
ventional serology (Skrindo et al., 2015). Some risk molecules reﬂected
region-speciﬁc differences in exposure. Themajor role of birch pollen in
Sweden is quite obvious due to the large diffusion of birch trees, while
for dust mites previous reports showed low prevalence of sensitization
to these species (Wickman et al., 2014; Rönmark et al., 2003). In otherese two at 16 years).
ity, % (95% CI) Speciﬁcity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
.2–37.2) 92.3 (84.8–96.9) 73.1 (52.2–88.4) 60.4 (51.8–68.6)
.6–31.7) 97.7 (91.9–99.7) 87.5 (61.7–98.4) 60.4 (51.8–68.6)
.3–36.1) 98.8 (93.6–100.0) 94.7 (74.0–99.9) 60.4 (51.8–68.6)
tive Value; NPV, Negative Predictive Value.
Table 2B
MAAS: Persistent asthma and/or rhinitis (with any of asthma or rhinitis at 3 yrs. and any of these two at 16 years).
Number of risk molecules at 3 yrs Freq.(%) TP FP TN FN Sensitivity (%) Speciﬁcity (%) PPV NPV
(95% CI) (95% CI) (95% CI) (95% CI)
0 57.9
1 21.1 4 0 4 7 36.4 (12.4–68.4) 100 (39.6–100) 100 (100−100) 36.4 (12.4–68.4)
2 15.8 3 0 4 7 30.0 (8.1–64.6) 100 (39.6–100) 100 (100–100) 36.4 (12.4–68.4)
3–5 5.3 1 0 4 7 12.5 (0.7–53.3) 100 (39.6–100) 100 (100–100) 36.4 (12.4–68.4)
TP, True Positive; FP, False Positive; TN, True Negative; FN, False Negative; PPV, Positive Predictive Value; NPV, Negative Predictive Value.
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appear and disappear depending on exposure.
4.2. Clinical Implication of Risk Allergen Molecules for Prediction of Onset
and Persistency of Allergic Airways Disease in Preschool Children
Sensitization to common food and inhalant allergen sources during
the ﬁrst year of life has been identiﬁed as a risk factor for development
of asthma and rhinitis at 6 years and for asthma in adults, but it has been
unclear how many and what allergen molecules in these allergen
sources are involved, thus making the use of IgE sensitization difﬁcult
to predict the development and persistence of respiratory allergic dis-
ease. Furthermore, previous studies have not assessed IgE to a combina-
tion of allergens in relation to development or prediction of disease
(Brockow et al., 2009; Rhodes et al., 2001).
Our study is the ﬁrst to show that indeed IgE reactivity to only few
allergen molecules in early childhood predicts respiratory allergy in ad-
olescence. The major allergens of cat (Fel d 1) and timothy grass pollen
(Phl p 1) were identiﬁed as risk allergens in both the BAMSE andMAAS
cohort. In fact, we have recently shown that Fel d 1 is not only a marker
of present but also a prognostic marker of future cat allergy (Asarnoj et
al., 2015). Furthermore, Phl p 1 has been identiﬁed as a molecule in the
beginning of grass pollen allergy (Hatzler et al., 2012). The results of the
present study also conﬁrm that themajor birch pollen allergen (Bet v 1)
is a risk allergen in Swedenwhile themajor allergens of dustmites (Der
p 1, and Der f 2) are risk allergens in the UK and in Germany (Posa et al.,
2017). However, it was unexpected to ﬁnd the peanut storage protein
Ara h 1 as a risk allergen in BAMSE since it represents a typical food al-
lergen. However, it has been suggested that sensitization toward food
allergens may also occur via the skin or the respiratory system
(Roberts and Lack, 2003; Brough et al., 2013). The results of the two
birth cohorts, where IgE reactivities to allergen molecules from more
than forty allergen sources were analyzed, indicate that a few allergen
molecules are sufﬁcient to provide a strong molecular signature to pre-
dict the development and persistence of allergic respiratory disease.
Previous efforts to predict asthma development during childhood
have shown limited capacity to predict which children with wheeze in
early childhood will develop asthma at a later age (Smit et al., 2015).
Based on our results it may therefore be possible to develop individual-
ized risk prediction charts for allergic respiratory diseases. Our results
indicate the possibility to develop allergen-speciﬁc forms of preventive
immunotherapy. Using approaches based on recombinant allergen de-
rivatives or synthetic allergen-derived peptide vaccines that are com-
posed of the identiﬁed risk allergen molecules could be designed
(Valenta et al., 2012; Zieglmayer et al., 2016; Valenta et al., 2017;
Campana et al., 2017).
The predictive values of IgE reactivity to increasing numbers of risk
molecules for incidence and persistence of asthma and/or rhinitis
were similar in the two cohorts indicating the generalizability of our
data. Since other risk factors could not be found in the analysis and
the risk molecules are linked to the environments in Sweden and the
UK, our data suggest that at early age there is a window of plasticity
andwith an opportunity tomodulate the immune system to escape dis-
ease development based on few allergen molecules. A very limited pro-
portion of childrenwith IgE reactivity to a speciﬁc allergenmolecule at acertain time point had IgE below the cutoff at the next follow up. Almost
all of these children had at the preceding time point an allergen-speciﬁc
IgE level below 1 ISU. This was shown for themajority of food allergens
molecules. The results are in line with previous reports where children
with low allergen-speciﬁc IgE levels have an increased tendency to out-
grow their allergies (Boyano-Martinez et al., 2002). However, our data
imply that for themajority of childrenwith IgE reactivity to common al-
lergens few become desensitized.
In conclusion, IgE reactivity early in life to a few risk allergen mole-
cules, from birch and timothy grass pollen as well as from cat and pea-
nut, to 95% predicts persistence of allergic airway disease up to
adolescence in a Swedish setting. Replication of data from the MAAS
birth cohort revealed similar results with a partially overlapping set of
few risk molecules related to differences in allergen exposure. Thus,
only a few allergen molecules are of importance for predicting onset
and persistency of respiratory allergic diseases and should be the
focus for preventive strategies and targets for novel therapies. The ﬁnd-
ings are of clinical importance for pediatricians or physicians seeing
children at a young age, who could perform early allergy diagnosis
with the key allergen molecules to initiate preventive measures.Contributors
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